trending Market Intelligence /marketintelligence/en/news-insights/trending/lnokey6woet9spkhoqxvma2 content esgSubNav
In This List

Clovis' Rubraca secures EU approval to treat recurring ovarian cancer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Clovis' Rubraca secures EU approval to treat recurring ovarian cancer

Clovis Oncology Inc. said the European Commission provided conditional authorization for its medicine Rubraca to treat women with a certain type of ovarian cancer.

The Boulder, Colo.-based biopharmaceutical company said Rubraca, which is also known as rucaparib, was approved as a treatment for BRCA mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who had been treated at least twice with chemotherapy and were unable to tolerate it any further.

The approval is conditional upon certain post-marketing commitments.

Clovis President and CEO Patrick Mahaffy said the company can now also submit a marketing authorization to use Rubraca as a treatment to stop the recurrence of cancer, an indication it is already approved for in the U.S.